Ezekowitz Alan sold $66K of FULC
Ezekowitz Alan sold 18,000 shares of Fulcrum Therapeutics, Inc. (FULC) at $3.65 on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings) and confirmation it was under a pre-arranged 10b5-1 plan.
Market read
This provides a fresh, auditable datapoint on insider activity but does not introduce new operating, regulatory, or financial guidance information.
What to watch
Traders may overreact to insider sales; the key differentiator here is the pre-arranged plan and the absence of any new company fundamentals in the filing.
Background
The article is an SEC Form 4 insider transaction disclosure for Fulcrum Therapeutics, Inc.
Ticker impact
Fulcrum Therapeutics director Ezekowitz Alan sold 18,000 shares at $3.6452 on 2026-06-26 under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by unusual volume or follow-on disclosures.
The filing is a director open-market sale executed under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change stated.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerFulcrum Therapeutics, Inc.
Subject of the Form 4 insider transaction; director Ezekowitz Alan sold shares under a 10b5-1 plan.
- insiderEzekowitz Alan
Director who reported the sale of 18,000 shares at $3.6452 on 2026-06-26.
